Dec 16, 2021 | Anocca in the news
Originally published in BioCentury. Anocca is using engineered human cells to recapitulate the T cell immune system ex vivo, eliminating the person-to-person variability in working with primary T cells from patients, to create standardized, scalable TCR-modified T...
Nov 9, 2021 | Anocca in the news
Södertälje, Sweden, 9 November 2021 – Anocca AB, a leader in unlocking the potential of T cell immunotherapy to deliver transformative T cell receptor engineered T cell therapeutics (TCR-T), today announced it has appointed a new Head of Clinical Development, Sandra...
Sep 8, 2021 | Press release
Södertälje, Sweden, 8 September 2021 – Anocca AB, a leader in unlocking the potential of T-cell immunotherapy to deliver transformative therapeutics, today announced the appointment of Jacob Michlewicz as Chief Financial Officer, effective immediately, and based at...
Sep 8, 2021 | Press release
Södertälje, 8 september 2021 – Anocca AB, ett världsledande svenskt bioteknikbolag för utveckling av T-cellsbehandlingar mot cancer, autoimmuna sjukdomar och virusinfektioner, tillkännagav idag utnämningen av Jacob Michlewicz till CFO, med omedelbar verkan. Han är...
Jul 26, 2021 | Anocca in the news
Originally published in Labiotech.eu. Swedish firm Anocca’s fundraising is the first major venture capital round to go to a European TCR therapy developer this year; another sign that the technology is gaining momentum. Last year was a busy one for companies...
We use cookies to ensure that we give you the best experience on our website.